Differentiation of Tumor Progression from Pseudoprogression in Patients with Posttreatment Glioblastoma Using Multiparametric Histogram Analysis
暂无分享,去创建一个
S. Kim | D. Kong | D. Nam | J. Cha | H. J. Kim | Y K Kim | P. Jeon | H-J Kim | S T Kim | Y. K. Kim | K H Kim | J Cha | B-J Kim | J Y Lee | P Jeon | D-S Kong | D-H Nam | K. Kim | P. Jeon | Y. Kim | D. H. Nam | S.T. Kim | B. Kim | J. Lee | J. Cha | H. Kim | B.-j. Kim | D. Kong | K. Kim | J. Lee
[1] D. Kong,et al. Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.
[2] A. Espeland,et al. Double reading of radiological examinations in Norway , 2011, Acta radiologica.
[3] S. Kim,et al. Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression , 2012, European Radiology.
[4] M. Chamberlain. Pseudoprogression in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Leland S. Hu,et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival , 2012, Neuro-oncology.
[6] M. Rosenthal,et al. Imaging modalities in high-grade gliomas: Pseudoprogression, recurrence, or necrosis? , 2012, Journal of Clinical Neuroscience.
[7] P. Box. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma , 2010 .
[8] Guy Marchal,et al. Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.
[9] R M Weisskoff,et al. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.
[10] G Johnson,et al. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. , 2007, AJNR. American journal of neuroradiology.
[11] A. Brandes,et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Namkug Kim,et al. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. , 2012, Radiology.
[13] J. Kim,et al. Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence. , 2010, Radiology.
[14] A G Sorensen,et al. Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma , 2011, American Journal of Neuroradiology.
[15] B. Rosen,et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis , 1996, Magnetic resonance in medicine.
[16] Y. Yoshii. Pathological review of late cerebral radionecrosis , 2008, Brain Tumor Pathology.
[17] Dieta Brandsma,et al. Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.
[18] G. Tung,et al. Diffusion-weighted MR imaging of rim-enhancing brain masses: is markedly decreased water diffusion specific for brain abscess? , 2001, AJR. American journal of roentgenology.
[19] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[20] A. Bjørnerud,et al. Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. , 2008, Radiology.
[21] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Boxerman,et al. The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard , 2012, American Journal of Neuroradiology.
[23] Andrew E. Sloan,et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.
[24] Toshinori Hirai,et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. , 2005, AJNR. American journal of neuroradiology.
[25] Dieta Brandsma,et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.
[26] Manish K. Aghi,et al. New advances that enable identification of glioblastoma recurrence , 2009, Nature Reviews Clinical Oncology.
[27] Bart Neyns,et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. , 2009, Surgical neurology.